Introduction
The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate.
Methods
Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed.
Results
A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P < 0.001), low PLR (HR 1.37, 95% CI 1.06–1.76, P = 0.013), low dNLR (HR 1.66, 95% CI 1.29–2.13, P < 0.001) and low SII (HR 1.63, 95% CI 1.18–2.04, P < 0.001) were independent prognostic factors for OS. Low NLR, PLR, dNLR and SII were also significant prognostic factors for PFS and LRRFS. Low NLR, low dNLR and low SII groups had better radiosensitivity than compared with high NLR, high dNLR and high SII groups (P = 0.001, P = 0.001 and P = 0.012).
Conclusion
NLR, PLR, dNLR and SII were independently associated with improved OS, PFS and LRRFS. Low NLR, dNLR and SII groups had better radiosensitivity. Immune inflammation biomarkers are promising prognostic predictors which can be obtained easily and inexpensively.